Compare Ascendis Pharma A/S (ASND) vs Comcast Corporation (CMCSA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Comcast Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Comcast Corporation trades at $23.6 (market cap $84.20B). The key difference: Comcast Corporation is far larger — about 4.7× Ascendis Pharma A/S's market cap, and Comcast Corporation pays a 5.6% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CMCSA | |
|---|---|---|
Market Cap | $17.74B | $84.20B |
Sector | Health | Media |
52-Week High | $277.18 | $33.81 |
52-Week Low | $163.32 | $22.32 |
Enterprise Value | $18.11B | $169.34B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CMCSA trades at $23.57, up 0.96% with strong fundamentals including a low P/E of 4.62 and net income margin of 15%. Recent earnings beats and a $2.14B acquisition of ITV's media unit signal strategic growth. Technicals are bearish with support at $23, while analyst consensus remains bullish with a $30.94 price target.
Outlook: Undervalued with robust cash flow and dividend yield, but weighed by bearish technicals and spin-off uncertainty. Key risks include integration challenges from acquisitions and competitive pressures in media and broadband sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
